Condition: HER2 Gene Mutation · Advanced Solid Tumors · Sponsor: Radiopharm Theranostics, Ltd
This is a first-in-human, Phase 0/1, open-label study of177Lu-RAD202 consisting of an Imaging Period with 177Lu-RAD202im(imaging dose) and a Treatment Period with 177Lu-RAD202tr(treatment dose) to determine the recommended dose(s) for future exploration of 177Lu-RAD202 in participants with HER2 expressing advanced solid tumours.
This description comes directly from the study's public registry record.
Dimitris Voliotis, MD · +1 646 535 5017 · dv@radiopharmtheranostics.com
Always discuss trial participation with your own doctor first.
| Nepean Hospital | Kingswood, New South Wales, Australia | Recruiting |
| Macquarie University Hospital | Macquarie Park, New South Wales, Australia | Recruiting |
| Wollongong Hospital | Wollongong, New South Wales, Australia | Recruiting |
| St Vincents Hospital, Melbourne | Fitzroy, Victoria, Australia | Not Yet Recruiting |
| GenesisCare Murdoch | Murdoch, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06824155